ALTHEA GROUP HOLDINGS LIMITED (AGH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
AGH - ALTHEA GROUP HOLDINGS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.031
19 Apr |
OPEN $0.03 |
HIGH $0.03 |
42,590 LOW $0.03 |
0.001| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | -3.9 |
| DPS All | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | 24.8 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | 7.8 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | -6.3 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | -55.29 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | -38.54 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | -35.65 % |
| Return on Assets | xxx | xxx | xxx | xxx | -26.17 % |
| Return on Equity | xxx | xxx | xxx | xxx | -38.54 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | -30.69 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -7.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | 4 M |
| Long Term Debt | xxx | xxx | xxx | xxx | 1 M |
| Total Debt | xxx | xxx | xxx | xxx | 5 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | 18 M |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 4 M |
| Price To Book Value | xxx | xxx | xxx | xxx | 0.55 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | 1.5 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | 5.99 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | 28 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 9 M |
| Research & Development | xxx | xxx | xxx | xxx | - |
| Investments - Total | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
AGH STOCK CHART
FNArena News on AGH
| 1 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
| 2 |
Mainstreaming Marijuana: Not What You’d ExpectSep 28 2020 - Weekly Reports |
| 3 |
Australian Broker Call *Extra* Edition – Jul 20, 2020Jul 20 2020 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
| 2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
| 3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
| 4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
| 5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
| 6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |